Title: Plasma Ghrelin Level and Nutritional Status in End Stage Kidney Diseased Patient Maintained on Hemodialysis
Authors: Mohammad Kamal Ghitany, Iman Ezzat El Gohary, Eman Zaki Azzam, Yasmine Saad Ahmed Mahmoud
DOI: http://dx.doi.org/10.18535/jmscr/v4i2.67
Abstract
Protein energy malnutrition is often present in patients with chronic kidney disease with or without ongoing renal replacement therapy Ghrelin is peptide hormone that consists of 28 amino acids with a molecular weight of about 3.3kDa.Ghrelin might have a role in the regulation of long term energy balance. So we conducted this study with the aim to investigate the changes in levels of serum ghrelin in HD patients and its relationship to nutritional status and inflammatory markers compared with healthy control. The study was conducted on 25 CKD patients maintained on hemodialysis and 20 healthy control subjects; the mean age of both groups was 47.92 ± 5.19years. Ghrelin concentration was significantly higher in patients on hemodialysis compared with healthy control subjects (p value = 0.002*) .CRP level was significantly higher in hemodialysis patients compared with healthy control (p= 0.001).Conclusion :there was significant increase in both CRP and ghrelin levels in malnourished hemodialysis patients than healthy control subjects.
Keywords: Ghrelin, CRP, Nutritional status.
References
1. Stenvinkel P, Lindholm B, Heimbu¨ rger O. Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease. Semin Dial 2004; 17: 505–515
2. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86:4753
3. Mak RH, Cheung W, Cone RD, Marks DL. Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease. PediatrNephrol 2005; 20(3):427-31
4. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, HosodaH,Kangawa K &Matsukura S (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J ClinEndocrinolMetab 87(1): 240–244
5. Mak RH, Cheung W. Therapeutic strategy for cachexia in chronic kidney disease. CurrOpinNephrolHypertens 2007; 16(6):542-6.
6. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences and therapy. Semin Dial 2002; 15: 329–37.
7. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int 2005; 67(4):1216-33.
8. Owoen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patientsundergoing hemodialysis. N Engl J Med 1993; 329(14):1001-6.
9. Heymsfield SB, McManus C, Smith J, Stevens V, Nixon DW. Anthropometric measurement of muscle mass. Revised equations for calculating bone-free arm muscle area. Am J ClinNutr 1982;36:680–90.
10. Jones CH, Wolfenden RC, Wells LM. Is subjective global assessment a reliable measure of nutritional status in hemodialysis 2007; 354-72.
11. Yoshimoto A, Mori K, Sugawara A, Mukoyama M, Yahata K, Suganami T, et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am SocNephrol 2002; 13(11):2748-52.
12. Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974;32(1):77-97.
13. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:1-253.
14. Itoh T, Nagaya N, Yoshikawa M, Fukuoka A, Takenaka H, Shimizu Y, et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2004;170:879-82.
15. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J ClinEndocrinolMetab 2002; 87:240-4
16. Chen CY, Asakawa A, Fujimiya M, Lee SD, Inui A. Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev 2009;61:430-81.
17. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease--what have we learned in 10 years? Semin Dial 2010;23:498-509.
18. Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle 2011;2:9-25.
19. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008;73:391-8.
20. Cuppari L, Kamimura MA. Avaliação-nutricionalnadoença renal crônica :desafiosnapráticaclínica. J Bras Nefrol 2009;31:28-35.